Q1 EPS Estimates for Zimmer Biomet Reduced by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Investment analysts at Zacks Research reduced their Q1 2025 earnings estimates for shares of Zimmer Biomet in a research report issued to clients and investors on Monday, January 20th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.01 per share for the quarter, down from their previous estimate of $2.02. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s FY2025 earnings at $8.46 EPS, Q1 2026 earnings at $2.25 EPS, Q2 2026 earnings at $2.33 EPS, Q4 2026 earnings at $2.32 EPS and FY2026 earnings at $9.10 EPS.

A number of other research analysts also recently issued reports on ZBH. BTIG Research dropped their price target on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a research note on Thursday, October 3rd. Truist Financial increased their price objective on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Evercore ISI decreased their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Raymond James dropped their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $123.33.

Zimmer Biomet Trading Up 0.9 %

Shares of NYSE:ZBH opened at $110.54 on Wednesday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The company’s 50 day moving average is $107.84 and its two-hundred day moving average is $108.04. The company has a market cap of $22.00 billion, a PE ratio of 21.02, a P/E/G ratio of 1.88 and a beta of 1.02. Zimmer Biomet has a 52 week low of $100.67 and a 52 week high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the business posted $1.65 EPS.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 18.25%.

Institutional Trading of Zimmer Biomet

Several hedge funds and other institutional investors have recently modified their holdings of ZBH. Geode Capital Management LLC lifted its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after buying an additional 125,852 shares during the last quarter. M&T Bank Corp grew its stake in Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after purchasing an additional 8,709 shares during the period. National Pension Service increased its stake in Zimmer Biomet by 3.8% in the third quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock valued at $39,893,000 after purchasing an additional 13,612 shares in the last quarter. Peddock Capital Advisors LLC bought a new position in shares of Zimmer Biomet in the 4th quarter worth $654,000. Finally, River Global Investors LLP increased its position in shares of Zimmer Biomet by 31.3% during the third quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock worth $2,276,000 after acquiring an additional 5,030 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.